Results 161 to 170 of about 516,686 (295)

Association Between Triglyceride-Glucose Index and Lung Function Parameters in the General Population Undergoing Health Examinations [PDF]

open access: yes
Yu Yang,1,2 Shuqi Wang,1,3 Boying Jia,1,3 Shuchun Chen1,3 1Department of Internal Medicine, Hebei Medical University, Shijiazhuang, People’s Republic of China; 2Department of Pharmacy, The Second Hospital of Hebei Medical University, Shijiazhuang, People’
Yang Y, Wang S, Jia B, Chen S
core  

Unveiling Endotypes in Systemic Lupus Erythematosus Through Multiomic Analysis: Insights Into Cardiovascular and Renal Complications

open access: yesArthritis &Rheumatology, EarlyView.
Objective Systemic lupus erythematosus (SLE) shows clinical and molecular heterogeneity, and cardiovascular (CV) complications and lupus nephritis (LN) remain leading causes of morbidity and mortality. This study investigated whether omic profiling can reveal molecular endotypes linked to these outcomes.
Tomás Cerdó   +84 more
wiley   +1 more source

Role of Triglyceride-Glucose Index in Type 2 Diabetes Mellitus and Its Complications [PDF]

open access: yes
Ying Pan,1 Mengjie Zhao,1 Tiantian Song,2 Jia Tang,2 Ming Kuang,2 Hongying Liu,2,* Shao Zhong3,* 1Department of General Practice, Kunshan Hospital Affiliated to Jiangsu University, Kunshan, Jiangsu, People’s Republic of China; 2Hangzhou Kang Ming
Liu H   +6 more
core  

Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity: Results From a Randomized Clinical Trial

open access: yesArthritis &Rheumatology, EarlyView.
Objective Overweight or obesity is prevalent in 72% to 82% of individuals with psoriatic arthritis (PsA). We assessed the efficacy and safety of ixekizumab (IXE) concomitantly administered with tirzepatide (TZP) compared with IXE alone in adult participants with active PsA and overweight with at least one weight‐related comorbidity or obesity.
Joseph F. Merola   +14 more
wiley   +1 more source

Deucravacitinib in Active Psoriatic Arthritis: Efficacy and Safety up to 52 Weeks From the Randomized, Double‐Blind, Phase 3 POETYK PsA‐2 Trial

open access: yesArthritis &Rheumatology, Accepted Article.
Objective To assess the efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with psoriatic arthritis (PsA) who were naive to biologic disease‐modifying antirheumatic drugs or received tumor necrosis factor inhibitors. Methods In the 52‐week (W), double‐blind, placebo‐controlled, phase 3 POETYK PsA‐2 study
Philip J. Mease   +20 more
wiley   +1 more source

Blood Lipid Levels and Their Value as Markers of Disease Activity in Severe Ulcerative Colitis

open access: yesInternational Journal of General Medicine
Lingling Zhu,1– 3 Linglin Tian,3 Suxia Li,1 Lijuan Huo3 1First Clinical Medical College, Shanxi Medical University, Taiyuan, Shanxi, People’s Republic of China; 2Linfen Vocational and Technical College, Linfen, Shanxi, People’s Republic of China ...
Zhu L, Tian L, Li S, Huo L
doaj  

Inhibition of hepatic microsomal triglyceride transfer protein – a novel therapeutic option for treatment of homozygous familial hypercholesterolemia

open access: yes, 2014
Alpo Vuorio,1,2 Matti J Tikkanen,3 Petri T Kovanen4 1Health Center Mehiläinen, Vantaa, Finland; 2Finnish Institute of Occupational Health, Lappeenranta, Finland; 3Heart and Lung Center, Helsinki University Central Hospital, Folkhälsan Research ...
Kovanen PT, Vuorio A, Tikkanen MJ
core  

Home - About - Disclaimer - Privacy